EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A large-scale study of peptide features defining immunogenicity of cancer neo-epitopes

Yat-Tsai Richie Wan iD, Zeynep Koşaloğlu-Yalçın iD, Bjoern Peters iD, Morten Nielsen iD

NAR Cancer · 2024

DOI: 10.1093/narcan/zcae002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift NAR Cancer, 2024. Verfasst von Yat-Tsai Richie Wan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Technology, Technical University of Denmark, Kgs. Lyngby, DK 28002, Denmark. Hauptthemen laut MEDLINE: Neoplasms, Epitopes, Peptides, Antigens, Neoplasm. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Accurate prediction of immunogenicity for neo-epitopes arising from a cancer associated mutation is a crucial step in many bioinformatics pipelines that predict outcome of checkpoint blockade treatments or that aim to design personalised cancer immunotherapies and vaccines. In this study, we performed a comprehensive analysis of peptide features relevant for prediction of immunogenicity using the Cancer Epitope Database and Analysis Resource (CEDAR), a curated database of cancer epitopes with experimentally validated immunogenicity annotations from peer-reviewed publications. The developed model, ICERFIRE (ICore-based Ensemble Random Forest for neo-epitope Immunogenicity pREdiction), extracts the predicted ICORE from the full neo-epitope as input, i.e. the nested peptide with the highest predicted major histocompatibility complex (MHC) binding potential combined with its predicted likelihood of antigen presentation (%Rank). Key additional features integrated into the model include assessment of the BLOSUM mutation score of the neo-epitope, and antigen expression levels of the wild-type counterpart which is often reflecting a neo-epitope's abundance. We demonstrate improved and robust performance of ICERFIRE over existing immunogenicity and epitope prediction models, both in cross-validation and on external validation datasets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsEpitopesPeptidesAntigens, NeoplasmHumansComputational BiologyMutationAntigen Presentation

Substanzen

EpitopesPeptidesAntigens, Neoplasm

Autor:innen und Institutionen

  • Department of Health Technology, Technical University of Denmark, Kgs. Lyngby, DK 28002, Denmark.
  • Center for Infectious Disease and Vaccine Research, La Jolla Institute of Immunology, La Jolla, CA 92037, USA.

ORCID-Profile: Yat-Tsai Richie Wan, Zeynep Koşaloğlu-Yalçın, Bjoern Peters, Morten Nielsen

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Wan, Y. R., Koşaloğlu-Yalçın, Z., Peters, B., & Nielsen, M. (2024). A large-scale study of peptide features defining immunogenicity of cancer neo-epitopes. NAR Cancer. https://doi.org/10.1093/narcan/zcae002

Vancouver

Wan YR, Koşaloğlu-Yalçın Z, Peters B, Nielsen M. A large-scale study of peptide features defining immunogenicity of cancer neo-epitopes. NAR Cancer. 2024. doi:10.1093/narcan/zcae002

BibTeX
@article{Wan2024,
  author = {Wan, Yat-Tsai Richie and Koşaloğlu-Yalçın, Zeynep and Peters, Bjoern and Nielsen, Morten},
  title = {A large-scale study of peptide features defining immunogenicity of cancer neo-epitopes},
  journal = {NAR Cancer},
  year = {2024},
  doi = {10.1093/narcan/zcae002}
}
Kostenlos starten →